Clinical Trial · NCT04422457

Specific Molecular Imaging of DX600 Labeled by PET Radionuclide Targeting ACE2 in Patients

Overview

Angiotensin-converting enzyme 2 (ACE2) plays an important role in renin-angiotensin system (RAS) and has been reported to relate with cancer. Recently, it has also been proved as the key target for COVID-19 infection. DX600 is a polypeptide that can specific binding to ACE2 specifically with nanomolar affinity reported in literature. This study constrcuted a radio-tracer, DX600 Labeled by PET Radionuclide, to monitoring biodistribution ACE2 in human beings, evaluate the detection ability of radio-tracer in ACE2 over-expression tumors and dynamic changes of ACE2 expression under therapy.

Sponsor

Peking University Cancer Hospital & Institute

Phase

N/A

ClinicalTrials.gov

NCT04422457

Eligibility

Inclusion

use 18F-FDG PET/CT as baseline evaluation
ECoG 0 or 1;

Exclusion

Cannot lie on their back for half an hour;
Suffering from claustrophobia or other mental diseases;
Significant hepatic or renal dysfunction;
Is Pregnant or ready to pregnant;
Refusal to join the clinical study;